Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington 98195, USA.
Pain Med. 2010 Jul;11(7):1010-6. doi: 10.1111/j.1526-4637.2010.00876.x. Epub 2010 May 18.
The objective of this study was the analysis of outcomes after intrathecal opioid treatment. Design. Retrospective chart review cohort study. Setting. Tertiary care university hospital and clinic. Patients. Adults of both sexes were included. Interventions. The intervention consisted of the implantation of intrathecal catheter and subcutaneous programmable pump to deliver opioids.
These included intrathecal and oral opioid consumption, self-reported pain levels, and complications.
We observed reduction of visual analog scale scores, decrease in oral opioid consumption. Stable long-term (3 year) pain reports. We also noted gradual increases in intrathecal opioid consumption. Pre-implant opioid consumption was inversely correlated with treatment success. The complication rate was approximately 20%.
We conclude that intrathecal opioids without adjunctive intrathecal medications have a favorable outcome. Some patients are able to eliminate oral opioids. Results seem stable for prolonged periods, although some increase in intrathecal opioids dosing may be required.
本研究的目的是分析鞘内阿片类药物治疗的结果。
回顾性图表审查队列研究。
三级护理大学医院和诊所。
纳入了男女两性成年人。
干预措施包括植入鞘内导管和皮下可编程泵以输送阿片类药物。
包括鞘内和口服阿片类药物的消耗、自我报告的疼痛水平和并发症。
我们观察到视觉模拟评分的降低,口服阿片类药物消耗的减少。稳定的长期(3 年)疼痛报告。我们还注意到鞘内阿片类药物消耗的逐渐增加。术前阿片类药物消耗与治疗效果呈负相关。并发症发生率约为 20%。
我们的结论是,没有辅助鞘内药物的鞘内阿片类药物具有良好的效果。一些患者能够消除口服阿片类药物。结果似乎稳定了很长一段时间,尽管可能需要增加鞘内阿片类药物的剂量。